Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients
Journal of Thoracic Disease Jan 12, 2018
Drzewiecka-Jedrzejczyk M, et al. - This study was designed to evaluate the prognostic value of matrix metalloproteinase (MMP)-2 and TIMP-2 concentrations in non-small cell lung carcinoma (NSCLC) patients. Findings demonstrated the correlation of serum MMP-2 and TIMP-2 concentrations with the tumour size and presence of metastases to lymph nodes. Data indicated that serum MMP-2 and TIMP-2 concentrations may serve as an auxiliary parameter indicating probability of a more advanced stage of lung cancer.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
